Biorestorative Therapies, Inc. (NASDAQ:BRTX) Sees Large Increase in Short Interest

Biorestorative Therapies, Inc. (NASDAQ:BRTX) was the recipient of a large growth in short interest during the month of May. As of May 29th, there was short interest totaling 6,588,718 shares, a growth of 1,687.2% from the May 14th total of 368,665 shares. Based on an average daily volume of 65,163,071 shares, the days-to-cover ratio is presently 0.1 days. Currently, 29.9% of the shares of the company are short sold.

Biorestorative Therapies Trading Up 9.0%

Biorestorative Therapies stock opened at $0.39 on Wednesday. Biorestorative Therapies has a 12-month low of $0.16 and a 12-month high of $2.05. The firm has a 50 day moving average of $0.27 and a 200 day moving average of $0.62. The firm has a market capitalization of $10.05 million, a price-to-earnings ratio of -0.37 and a beta of 0.67.

Biorestorative Therapies (NASDAQ:BRTX) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.01. Biorestorative Therapies had a negative net margin of 3,088.27% and a negative return on equity of 508.42%. The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.31 million. On average, analysts predict that Biorestorative Therapies will post -0.66 EPS for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biorestorative Therapies in a research report on Wednesday, May 27th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.

Institutional Investors Weigh In On Biorestorative Therapies

A number of institutional investors have recently added to or reduced their stakes in the stock. DRW Securities LLC purchased a new stake in Biorestorative Therapies during the 4th quarter valued at approximately $55,000. Citadel Advisors LLC purchased a new stake in Biorestorative Therapies during the 3rd quarter valued at approximately $152,000. Finally, Virtu Financial LLC grew its holdings in Biorestorative Therapies by 102.4% during the 3rd quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock valued at $35,000 after buying an additional 12,319 shares in the last quarter. 69.38% of the stock is owned by hedge funds and other institutional investors.

Biorestorative Therapies Company Profile

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.